US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ASCENTAGE PHARMA GROUP

24.52

+0.33001.36%

Post-market: 24.520.00000.00%16:10 EST

Volume:1.64K

Turnover:39.73K

Market Cap:2.29B

PE:-12.39

High:24.53

Open:23.66

Low:23.66

Close:24.19

52wk High:48.45

52wk Low:17.09

Shares:93.33M

Float Shares:71.58M

Volume Ratio:0.47

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9795

EPS(LYR):-0.7356

ROE:-159.65%

ROA:-22.77%

PB:23.83

PE(LYR):-33.34

Loading ...

Overview Company News Filings

Ascentage Pharma Says Bruton's Tyrosine Kinase-Targeted Protein Degrader Application Gets China Clearance

MT Newswires Live

Ascentage Pharma announces IND clearance by the China CDE for APG-3288

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288

ASCENTAGE-B Stock Surges Over 3% in Intraday Trading as BTK Degrader Class 1 New Drug APG-3288 Tablets Gain Clinical Approval

Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference

Ascentage Pharma initiated with a Buy at Rodman & Renshaw

Piper Sandler Reaffirms Their Buy Rating on Ascentage Pharma Group International Unsponsored ADR (AAPG)

Ascentage Pharma Gets FDA's IND Clearance for APG-3288

MT Newswires Live

Hong Kong Stock Movement | ASCENTAGE-B (06855) Rises Nearly 4% as Novel BTK Degrader APG-3288's IND Application Receives US FDA Clearance

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

ASCENTAGE PHARMA GROUP-B (06855): David Sidransky to be Appointed as Lead Independent Non-Executive Director

CICC Maintains "Outperform" Rating on ASCENTAGE-B (06855) as POLARIS-1 Gains Approval in US and EU

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

HK Stock Movement | ASCENTAGE-B (06855) Rises Over 6% as POLARIS-1 Study for Olverembatinib (Nerlynx®) Gains FDA and EMA Approval

ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AAPG/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"ASCENTAGE PHARMA GROUP","latestPrice":24.52,"timestamp":1770411600000,"preClose":24.19,"halted":0,"volume":1637,"hourTrading":{"tag":"盘后","latestPrice":24.52,"preClose":24.52,"latestTime":"16:10 EST","volume":110,"amount":2726.9,"timestamp":1770412204675,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.013642000826787858,"floatShares":71582800,"shares":93330405,"eps":-1.979486,"marketStatus":"Market Closed","change":0.33,"latestTime":"02-06 16:00:00 EST","open":23.6625,"high":24.53,"low":23.6625,"amount":39733.4608,"amplitude":0.035862,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.979486,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":24.19,"postHourTrading":{"tag":"盘后","latestPrice":24.52,"preClose":24.52,"latestTime":"16:10 EST","volume":110,"amount":2726.9,"timestamp":1770412204675,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4724386928905639},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":0.4724386928905639,"shares":93330405,"dividePrice":0,"high":24.53,"amplitude":0.035862,"preClose":24.19,"low":23.6625,"week52Low":17.09,"pbRate":"23.83","psRate":"40.62","week52High":48.45,"institutionHeld":0,"latestPrice":24.52,"eps":-1.979486,"divideRate":0,"volume":1637,"delay":0,"ttmEps":-1.979486,"open":23.6625,"prevYearClose":26.24,"prevWeekClose":24.18,"prevMonthClose":24.18,"prevQuarterClose":26.24,"fiveDayClose":24.18,"twentyDayClose":27.89,"sixtyDayClose":32.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"Pre-Market","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1764910800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2026-02-05","current":-12.387054,"percent":0.992218,"low":-76.454813,"twenty":-42.799161,"median":-30.329245,"eighty":-18.340784,"high":-12.826422,"avg":-32.674789,"sd":16.299632,"marketCap":2234564723.11},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-12","current":-22.941741,"twenty":-59.475774,"median":-35.943012,"eighty":-31.122625,"marketCap":3735810338.07},{"date":"2025-09-19","current":-21.785524,"twenty":-59.316014,"median":-35.857966,"eighty":-29.943039,"marketCap":3550375801.58},{"date":"2025-09-26","current":-21.102028,"twenty":-59.062646,"median":-35.66937,"eighty":-29.751262,"marketCap":3428719452.06},{"date":"2025-10-03","current":-22.266298,"twenty":-59.025902,"median":-35.30284,"eighty":-28.699054,"marketCap":3625414266.5},{"date":"2025-10-10","current":-21.050291,"twenty":-58.738293,"median":-35.189473,"eighty":-26.732175,"marketCap":3423480133.18},{"date":"2025-10-17","current":-19.80269,"twenty":-58.191808,"median":-34.731922,"eighty":-24.468638,"marketCap":3221889328.22},{"date":"2025-10-24","current":-19.801335,"twenty":-57.904825,"median":-34.477812,"eighty":-23.569995,"marketCap":3222890223.42},{"date":"2025-10-31","current":-19.321494,"twenty":-57.532716,"median":-34.141844,"eighty":-22.943557,"marketCap":3150231208.59},{"date":"2025-11-07","current":-18.112503,"twenty":-56.69325,"median":-33.992043,"eighty":-22.558349,"marketCap":2949090425.48},{"date":"2025-11-14","current":-19.583345,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"marketCap":3199584585.23},{"date":"2025-11-21","current":-17.547753,"twenty":-55.765092,"median":-33.408485,"eighty":-22.122489,"marketCap":2860955000.96},{"date":"2025-11-28","current":-18.539078,"twenty":-55.318442,"median":-33.361942,"eighty":-21.796498,"marketCap":3034915066.08},{"date":"2025-12-05","current":-18.33416,"twenty":-53.27811,"median":-33.187028,"eighty":-21.590149,"marketCap":3005486168.49},{"date":"2025-12-12","current":-17.062052,"twenty":-48.796704,"median":-32.920123,"eighty":-21.073758,"marketCap":2802301628.68},{"date":"2025-12-19","current":-16.188794,"twenty":-48.517949,"median":-32.72391,"eighty":-20.125041,"marketCap":2665447409.6},{"date":"2025-12-26","current":-15.347054,"twenty":-48.514967,"median":-32.664532,"eighty":-19.801335,"marketCap":2537308174.25},{"date":"2026-01-02","current":-14.520508,"twenty":-48.239817,"median":-32.57809,"eighty":-19.656119,"marketCap":2406972911.39},{"date":"2026-01-09","current":-15.636938,"twenty":-46.480698,"median":-32.420873,"eighty":-19.300607,"marketCap":2595562368.02},{"date":"2026-01-16","current":-14.792082,"twenty":-45.997596,"median":-31.846105,"eighty":-19.073232,"marketCap":2461528990.12},{"date":"2026-01-23","current":-14.451393,"twenty":-45.706429,"median":-31.242401,"eighty":-18.892753,"marketCap":2402559084.95},{"date":"2026-01-30","current":-13.594278,"twenty":-43.897892,"median":-30.891003,"eighty":-18.486342,"marketCap":2268064814.82},{"date":"2026-02-05","current":-13.373823,"twenty":-42.799161,"median":-30.329245,"eighty":-18.340784,"marketCap":2234564723.11}],"updateTime":1770453489321},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609569413","title":"Ascentage Pharma Says Bruton's Tyrosine Kinase-Targeted Protein Degrader Application Gets China Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2609569413","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609569413?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:52","pubTimestamp":1770371561,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (AAPG) said late Thursday that China Center for Drug Evaluation cleared the company's investigational new drug application for Bruton's tyrosine kinase-targeted pr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2609533250","title":"Ascentage Pharma announces IND clearance by the China CDE for APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533250","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533250?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:35","pubTimestamp":1770334517,"startTime":"0","endTime":"0","summary":"Ascentage Pharma (AAPG) “announced that its novel next-generation Bruton’s tyrosine kinase-targeted protein degrader, APG-3288, has received invest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-announces-ind-clearance-by-the-china-cde-for-apg-3288-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-announces-ind-clearance-by-the-china-cde-for-apg-3288-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2125909759.SGD","LU2125909916.SGD","AAPG","BK4139","LU1223082519.USD","LU1223083913.SGD","BK4129","LU1223082196.USD","LU1923622291.USD","APG","BK4017","CDE","IND"],"gpt_icon":0},{"id":"2609533068","title":"Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533068","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533068?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:30","pubTimestamp":1770334200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Feb.  05, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3233530/0/en/Ascentage-Pharma-Announces-IND-Clearance-by-the-China-CDE-for-BTK-Degrader-APG-3288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2240825500.USD","LU1223082196.USD","LU2089283258.USD","LU1923622291.USD","LU2023251221.USD","LU0124676726.USD","IND","LU1712237335.SGD","BK4588","LU1223083913.SGD","LU2041044095.USD","LU2271345857.HKD","PK","LU1939255532.USD","LU1892829315.USD","LU2463526074.USD","LU2238339852.HKD","LU1430594728.SGD","LU0511384066.AUD","BK4585","LU2125909916.SGD","LU2413666426.HKD","WM","LU1917777945.USD","LU1923621640.USD","BCR","LU2125909759.SGD","AAPG","LU0347712357.USD","BK4181","LU0289960550.SGD","LU2106854487.HKD","LU2298064838.USD","LU2111349929.HKD","LU2362540622.SGD","LU2362541513.USD","CDE","LU2308191902.HKD","APG","LU1989772840.SGD","LU2089284900.SGD","LU2413666699.HKD","LU0289739343.SGD","LU1989772923.USD","LU0158827948.USD","BK4139","BK4533","LU0057025933.USD","LU0472753341.HKD","LU2023250504.SGD"],"gpt_icon":0},{"id":"1128142501","title":"ASCENTAGE-B Stock Surges Over 3% in Intraday Trading as BTK Degrader Class 1 New Drug APG-3288 Tablets Gain Clinical Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1128142501","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128142501?lang=en_us&edition=fundamental","pubTime":"2026-02-04 11:12","pubTimestamp":1770174738,"startTime":"0","endTime":"0","summary":"Shares of ASCENTAGE PHARMA GROUP - B (06855) climbed more than 3% during the trading session. At the time of writing, the stock was up 1.38%, trading at HK$45.88, with a turnover of HK$36.975...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1574","LU2125909916.SGD","BK1161","APG","BK4129","LU1923622291.USD","06855","AAPG","LU2125909759.SGD"],"gpt_icon":0},{"id":"2603216076","title":"Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603216076","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603216076?lang=en_us&edition=fundamental","pubTime":"2026-01-15 09:25","pubTimestamp":1768440300,"startTime":"0","endTime":"0","summary":"Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation BTK protein degrader APG-3288 receives IND clearance f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/15/3219202/0/en/Ascentage-Pharma-Outlined-its-Global-Innovation-Strategy-During-Presentation-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","LABU","LU0314104364.USD","LU1791710400.SGD","LU0795875169.SGD","LU2028103732.USD","XBI","LU2133065610.SGD","LU0158827781.USD","LU0234570918.USD","IND","BK4127","HCSG","LU1162221912.USD","LU1363072403.SGD","BK4581","BK4588","LU0128526141.USD","IE00BZ1G4Q59.USD","LU1548497426.USD","LU0006306889.USD","LU0912757837.SGD","BK4139","XLV","LU0267386448.USD","LU0882574139.USD","LU1244550494.USD","LU1732799900.SGD","LU1244550577.SGD","LU0795875086.SGD","LU0106261372.USD","LU1732800096.USD","LU0158827948.USD","LU2089284900.SGD","LU0029874061.USD","LU2111349929.HKD","BK4534","LU1791710582.SGD","LU1720051108.HKD","BK4585","LU2089283258.USD","LU0225283273.USD","LU1668664300.SGD","LU1989772840.SGD","LU1989772923.USD","IE00BKVL7J92.USD","LU2271345857.HKD","AAPG","BK4137","LU2347655156.SGD"],"gpt_icon":0},{"id":"2603598630","title":"Ascentage Pharma initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2603598630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603598630?lang=en_us&edition=fundamental","pubTime":"2026-01-14 04:20","pubTimestamp":1768335631,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $48 price target Published first on TheFly – the ultimate sour...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-rodman-renshaw-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2601369153","title":"Piper Sandler Reaffirms Their Buy Rating on Ascentage Pharma Group International Unsponsored ADR (AAPG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369153?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:17","pubTimestamp":1767874648,"startTime":"0","endTime":"0","summary":"In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Ascentage Pharma Group International Unsponsored ADR, with a p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-ascentage-pharma-group-international-unsponsored-adr-aapg-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-ascentage-pharma-group-international-unsponsored-adr-aapg-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAPG"],"gpt_icon":0},{"id":"2601314871","title":"Ascentage Pharma Gets FDA's IND Clearance for APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601314871","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601314871?lang=en_us&edition=fundamental","pubTime":"2026-01-07 18:12","pubTimestamp":1767780754,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group (AAPG) said late Tuesday it has received an investigational new drug clearance from the US Food and Drug Administration for oncology drug candidate APG-3288.The company plans to advance the drug into a phase 1 trial in patients with relapsed/refractory B-cell malignancies.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU2125909759.SGD","APG","BK4129","AAPG","LU2125909916.SGD","IND","LU1923622291.USD"],"gpt_icon":0},{"id":"1146349455","title":"Hong Kong Stock Movement | ASCENTAGE-B (06855) Rises Nearly 4% as Novel BTK Degrader APG-3288's IND Application Receives US FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=1146349455","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146349455?lang=en_us&edition=fundamental","pubTime":"2026-01-07 11:10","pubTimestamp":1767755435,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) rose nearly 4%, and as of the time of writing, it was up 3.69% to HK$53.4, with a turnover of HK$61.6418 million.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909759.SGD","LU2125909916.SGD","BK1574","AAPG","BK4139","06855","BK1161","BK4129","LU1923622291.USD","APG"],"gpt_icon":0},{"id":"2601479768","title":"Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601479768","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601479768?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:00","pubTimestamp":1767747600,"startTime":"0","endTime":"0","summary":"Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has receivedinvestigational new drug (IND) clearancefrom the U.S. FDA, marking another major expansion to the comp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214213/0/en/Ascentage-Pharma-Announces-IND-Clearance-by-the-U-S-Food-and-Drug-Administration-for-BTK-Degrader-APG-3288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0124676726.USD","WM","LU2125909916.SGD","LU2362541513.USD","BK4129","BK4585","LU1623119135.USD","BCR","LU0057025933.USD","LU2125910179.SGD","LU0069063385.USD","LU1430594728.SGD","LU2041044095.USD","LU2211814178.USD","LU2355687059.USD","LU1917777945.USD","LU1923622291.USD","LU1923621640.USD","BK4181","LU1892829315.USD","LU0289739343.SGD","BK4534","LU2125910336.SGD","LU2308191902.HKD","LU2362540622.SGD","LU1939255532.USD","LU0511384066.AUD","AAPG","BK4120","PK","APG","IND","LU2089279066.USD","LU0689626769.HKD","LU2238339852.HKD","BK4588","LU2240825500.USD","LU0347712357.USD","LU0472753341.HKD","LU1712237335.SGD","LU2229751404.USD","LU0289961442.SGD","LU1585245621.USD","LU1989772840.SGD","LU2023250504.SGD","LU2125909759.SGD","LU2413666699.HKD","LU1974910355.USD","BK4139"],"gpt_icon":0},{"id":"1168013082","title":"ASCENTAGE PHARMA GROUP-B (06855): David Sidransky to be Appointed as Lead Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1168013082","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168013082?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:50","pubTimestamp":1767106220,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA GROUP-B (06855) announced that Dr. Debra Yu will be appointed as an additional member of the Board Nomination Committee, effective December 26, 2025. Dr. David Sidransky will be...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","BK4139","AAPG","BK1161"],"gpt_icon":0},{"id":"1177837504","title":"CICC Maintains \"Outperform\" Rating on ASCENTAGE-B (06855) as POLARIS-1 Gains Approval in US and EU","url":"https://stock-news.laohu8.com/highlight/detail?id=1177837504","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177837504?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:57","pubTimestamp":1765943833,"startTime":"0","endTime":"0","summary":"CICC has reiterated its \"Outperform\" rating on ASCENTAGE-B (06855) with a target price of HK$89, citing positive progress in the company's R&D pipeline. The global Phase III study (POLARIS-1) for...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1161","BK1574","06855","AAPG"],"gpt_icon":0},{"id":"2590677273","title":"ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590677273","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590677273?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapyMolecular responses continue to deepen with extended treatment duration, reaching 60% m","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202020/0/en/ASH-2025-Updated-Data-for-Ascentage-Pharma-s-Olverembatinib-in-Second-Line-CML-CP-Showing-Encouraging-Potential-for-Early-Line-Treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","BK4139","LU2463526074.USD","AAPG","CP","BK4016","BK4585","BK4588","BK4109","LU1261432733.SGD"],"gpt_icon":0},{"id":"2590367742","title":"ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367742","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590367742?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectivelyHigh-risk IKZF1plus patient","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202021/0/en/ASH-2025-Ascentage-Pharma-Presents-First-Dataset-from-Phase-III-POLARIS-1-Study-of-Olverembatinib-in-Newly-Diagnosed-Ph-ALL-Shows-a-Best-MRD-Negativity-CR-Rate-Exceeding-60.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4533","ASH","AAPG","LU2355687059.USD","LU1571399168.USD","LU2463526074.USD","BK4109","LU0985320562.USD","LU1699723380.USD","BK4139","BK4081","ALL","BK4585","CR","BK4134","EMA","BK4588","BK4107","BK4161"],"gpt_icon":0},{"id":"2590367726","title":"ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367726","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590367726?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:45","pubTimestamp":1765241100,"startTime":"0","endTime":"0","summary":"Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effect","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202022/0/en/ASH-2025-Ascentage-Pharma-Presents-Four-Year-Follow-Up-Data-from-Registrational-Phase-II-Study-of-Olverembatinib-Reaffirming-Differentiated-Long-Term-Efficacy-and-Safety-in-TKI-Res.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2463526074.USD","ASH","BK4016","BK4077","BK4139","BK4588","LU1261432733.SGD","CHR","CP","BK4109","AAPG"],"gpt_icon":0},{"id":"2589807890","title":"ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances","url":"https://stock-news.laohu8.com/highlight/detail?id=2589807890","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589807890?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:10","pubTimestamp":1765156200,"startTime":"0","endTime":"0","summary":"Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diag","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201167/0/en/ASH-2025-Ascentage-Pharma-Presents-Encouraging-Data-from-Phase-Ib-II-Study-of-Bcl-2-Inhibitor-Lisaftoclax-in-Venetoclax-Exposed-Patients-with-Myeloid-Malignances.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","BK4203","HR","BK4097","LU2463526074.USD","OS","AAPG","ORR","BK4109","BK4139","BK4225"],"gpt_icon":0},{"id":"2589066826","title":"Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589066826","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589066826?lang=en_us&edition=fundamental","pubTime":"2025-12-06 23:15","pubTimestamp":1765034100,"startTime":"0","endTime":"0","summary":"Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201070/0/en/Ascentage-Pharma-Presents-Pivotal-China-Registrational-Study-Data-for-Lisaftoclax-in-Oral-Report-at-2025-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK4203","BK4225","BK4139","TLS","ORR","BK4117","LU2463526074.USD","BK4109","BK4097","AFG","ASH","HR","BK4107"],"gpt_icon":0},{"id":"1170778758","title":"HK Stock Movement | ASCENTAGE-B (06855) Rises Over 6% as POLARIS-1 Study for Olverembatinib (Nerlynx®) Gains FDA and EMA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1170778758","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170778758?lang=en_us&edition=fundamental","pubTime":"2025-12-05 09:38","pubTimestamp":1764898699,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) surged more than 6%, reaching HK$64.2 by the time of writing, with a trading volume of HK$19.93 million. The uptick follows the company's announcement on December 5 that its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4139","AAPG","06855","BK4081","EMA","BK1574"],"gpt_icon":0},{"id":"1151522256","title":"ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL","url":"https://stock-news.laohu8.com/highlight/detail?id=1151522256","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151522256?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:08","pubTimestamp":1764893308,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA-B (06855) announced that its self-developed Class 1 innovative drug, olverembatinib (brand name: Nerlynx®), has received approval from the U.S. Food and Drug Administration (FDA) and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","ALL","BK1574","06855","BK4134","LU0985320562.USD","III","LU1571399168.USD","BK1161","AAPG","BK4081","EMA","BK4139","BK4533","LU1699723380.USD","LU2355687059.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2589550638","title":"Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2589550638","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589550638?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:00","pubTimestamp":1764892800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Dec.  04, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International(NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200415/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Olverembatinib-in-First-Line-Treatment-of-Ph-ALL-Cleared-by-US-FDA-and-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","LU0234570918.USD","LU2506952097.USD","LU0348723411.USD","SG9999015986.USD","CSCO","LU1244550577.SGD","ASH","BK4134","EMA","LU1066051225.USD","LU0985320562.USD","BK4579","CR","LU0203347892.USD","CDE","BK4585","LU0868494708.USD","LU1929549753.HKD","IE00BFXG1179.USD","AAPG","BK4020","LU1599440770.SGD","IE00BDGV0183.EUR","BK4581","LU1244550221.USD","IE00BVYPNW00.USD","LU1571399168.USD","LU2286300806.USD","BK4017","BK4525","IE00BZ1G4Q59.USD","IE00BFMHRM44.USD","LU1674673428.USD","BK4560","LU1221951046.USD","OS","LU1894683348.USD","BK4139","LU1880398471.USD","LU2237443382.USD","LU1221951129.SGD","LU0868494617.USD","IE00B3PB1722.GBP","LU0792757196.USD","III","LU1778281490.HKD","ALL","BK4161"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":49,"code":"91000000","status":"200"}]}}